A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting

Phase 1

Phase 2

Glofitamab & ChemoimmunotherapyA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Sponsor:

Hoffmann-La Roche

Code:

NCT05533775

Conditions

Mature B-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 6 - 30

Healthy Volunteers: Not accepted

Interventions

Obinutuzumab

Glofitamab

Rituximab

Ifosfamide

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-08-01.